Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 195Prostatic Neoplasms, Castration-Resistant 20Neoplasm Metastasis 20Metastatic Castration Resistant Prostate Cancer 10Prostate Cancer Metastatic 7Metastatic Castration-Resistant Prostate Cancer 7Metastatic Castration-resistant Prostate Cancer 6Neoplasms 5Castration-resistant Prostate Cancer 5Breast Neoplasms 5Pancreatic Neoplasms 4Melanoma 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Bulbo-Spinal Atrophy, X-Linked 4Adenocarcinoma 4Urinary Bladder Neoplasms 3Prostate Adenocarcinoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Carcinoma, Renal Cell 3Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Prostatic Diseases 2Ovarian Neoplasms 2Non-metastatic Castration-resistant Prostate Cancer 2Metastatic Hormone-sensitive Prostate Cancer 2Metastatic Hormone Sensitive Prostate Cancer 2

Interventions

enzalutamide 2Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Metastatic Hormone Sensitive Prostate Cancer × enzalutamide × Genitourinary × Clear all
NCT04076059 2026-04-17

China ARCHES

Astellas Pharma Inc

Phase 3 Active not recruiting
180 enrolled 24 charts
Genitourinary

Metastatic Hormone Sensitive Prostate Cancer

NCT02677896 2025-10-24

ARCHES

Astellas Pharma Inc

Phase 3 Completed
1,150 enrolled 23 charts 1 FDA
Genitourinary

Metastatic Hormone Sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡